Sign up
Healthed-White-on-Blue

New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Andrew Sindone AM

Prof Andrew Sindone AM

MRAs for Heart Failure Update - New Developments

Prof David Price

Prof David Price

COPD Exacerbation – Inhaled steroids vs Pneumonia Risks – It's Not Black and White

A/Prof Ralph Audehm & Prof Simone Strasser

A/Prof Ralph Audehm & Prof Simone Strasser

Abnormal LFTs – Practical Cases Expert Q&A

Angela Newbound

Angela Newbound

Practical Strategies to Increase Vaccination Rates This Flu Season

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

28 April 2026
Register Now
Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970

Discover

Healthed

CPD platform